Review




Structured Review

Proteintech frem1
IHC and IF staining of functional proteins. (a) H&E and Masson's staining of defect area after implantation of CPH/rGO-3/0 and CPH/rGO-3/0.6 scaffolds for one month. (b) OCN IHC and IF staining of CPH/rGO-3/0 and CPH/rGO-3/0.6 after implantation for one month and the corresponding OD value and fluorescence intensity statistics. (c) IF staining of <t>FREM1</t> and ANK3 in scaffolds after implanting for one months in rats and corresponding fluorescence intensity statistics. (d) IF staining of KCNN3 and KCNH1 in scaffolds after implanting for one months in rats and corresponding fluorescence intensity statistics. n = 20 per group. Data are expressed as mean ± SD. ∗ for p < 0.05; ∗∗ for p < 0.01; ∗∗∗ for p < 0.001.
Frem1, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/frem1/product/Proteintech
Average 90 stars, based on 1 article reviews
frem1 - by Bioz Stars, 2026-06
90/100 stars

Images

1) Product Images from "A continuous adhesion-enhanced osteogenic pathway in artificial scaffold drives cellular infiltration and condensed mineralization for rapid bone regeneration"

Article Title: A continuous adhesion-enhanced osteogenic pathway in artificial scaffold drives cellular infiltration and condensed mineralization for rapid bone regeneration

Journal: Bioactive Materials

doi: 10.1016/j.bioactmat.2026.02.026

IHC and IF staining of functional proteins. (a) H&E and Masson's staining of defect area after implantation of CPH/rGO-3/0 and CPH/rGO-3/0.6 scaffolds for one month. (b) OCN IHC and IF staining of CPH/rGO-3/0 and CPH/rGO-3/0.6 after implantation for one month and the corresponding OD value and fluorescence intensity statistics. (c) IF staining of FREM1 and ANK3 in scaffolds after implanting for one months in rats and corresponding fluorescence intensity statistics. (d) IF staining of KCNN3 and KCNH1 in scaffolds after implanting for one months in rats and corresponding fluorescence intensity statistics. n = 20 per group. Data are expressed as mean ± SD. ∗ for p < 0.05; ∗∗ for p < 0.01; ∗∗∗ for p < 0.001.
Figure Legend Snippet: IHC and IF staining of functional proteins. (a) H&E and Masson's staining of defect area after implantation of CPH/rGO-3/0 and CPH/rGO-3/0.6 scaffolds for one month. (b) OCN IHC and IF staining of CPH/rGO-3/0 and CPH/rGO-3/0.6 after implantation for one month and the corresponding OD value and fluorescence intensity statistics. (c) IF staining of FREM1 and ANK3 in scaffolds after implanting for one months in rats and corresponding fluorescence intensity statistics. (d) IF staining of KCNN3 and KCNH1 in scaffolds after implanting for one months in rats and corresponding fluorescence intensity statistics. n = 20 per group. Data are expressed as mean ± SD. ∗ for p < 0.05; ∗∗ for p < 0.01; ∗∗∗ for p < 0.001.

Techniques Used: Staining, Functional Assay, Fluorescence



Similar Products

90
Proteintech frem1
IHC and IF staining of functional proteins. (a) H&E and Masson's staining of defect area after implantation of CPH/rGO-3/0 and CPH/rGO-3/0.6 scaffolds for one month. (b) OCN IHC and IF staining of CPH/rGO-3/0 and CPH/rGO-3/0.6 after implantation for one month and the corresponding OD value and fluorescence intensity statistics. (c) IF staining of <t>FREM1</t> and ANK3 in scaffolds after implanting for one months in rats and corresponding fluorescence intensity statistics. (d) IF staining of KCNN3 and KCNH1 in scaffolds after implanting for one months in rats and corresponding fluorescence intensity statistics. n = 20 per group. Data are expressed as mean ± SD. ∗ for p < 0.05; ∗∗ for p < 0.01; ∗∗∗ for p < 0.001.
Frem1, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/frem1/product/Proteintech
Average 90 stars, based on 1 article reviews
frem1 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

91
Proteintech rabbit anti frem1
IHC and IF staining of functional proteins. (a) H&E and Masson's staining of defect area after implantation of CPH/rGO-3/0 and CPH/rGO-3/0.6 scaffolds for one month. (b) OCN IHC and IF staining of CPH/rGO-3/0 and CPH/rGO-3/0.6 after implantation for one month and the corresponding OD value and fluorescence intensity statistics. (c) IF staining of <t>FREM1</t> and ANK3 in scaffolds after implanting for one months in rats and corresponding fluorescence intensity statistics. (d) IF staining of KCNN3 and KCNH1 in scaffolds after implanting for one months in rats and corresponding fluorescence intensity statistics. n = 20 per group. Data are expressed as mean ± SD. ∗ for p < 0.05; ∗∗ for p < 0.01; ∗∗∗ for p < 0.001.
Rabbit Anti Frem1, supplied by Proteintech, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti frem1/product/Proteintech
Average 91 stars, based on 1 article reviews
rabbit anti frem1 - by Bioz Stars, 2026-06
91/100 stars
  Buy from Supplier

91
Proteintech proteintech 13086 1 ap
IHC and IF staining of functional proteins. (a) H&E and Masson's staining of defect area after implantation of CPH/rGO-3/0 and CPH/rGO-3/0.6 scaffolds for one month. (b) OCN IHC and IF staining of CPH/rGO-3/0 and CPH/rGO-3/0.6 after implantation for one month and the corresponding OD value and fluorescence intensity statistics. (c) IF staining of <t>FREM1</t> and ANK3 in scaffolds after implanting for one months in rats and corresponding fluorescence intensity statistics. (d) IF staining of KCNN3 and KCNH1 in scaffolds after implanting for one months in rats and corresponding fluorescence intensity statistics. n = 20 per group. Data are expressed as mean ± SD. ∗ for p < 0.05; ∗∗ for p < 0.01; ∗∗∗ for p < 0.001.
Proteintech 13086 1 Ap, supplied by Proteintech, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proteintech 13086 1 ap/product/Proteintech
Average 91 stars, based on 1 article reviews
proteintech 13086 1 ap - by Bioz Stars, 2026-06
91/100 stars
  Buy from Supplier

91
Proteintech anti frem1
IHC and IF staining of functional proteins. (a) H&E and Masson's staining of defect area after implantation of CPH/rGO-3/0 and CPH/rGO-3/0.6 scaffolds for one month. (b) OCN IHC and IF staining of CPH/rGO-3/0 and CPH/rGO-3/0.6 after implantation for one month and the corresponding OD value and fluorescence intensity statistics. (c) IF staining of <t>FREM1</t> and ANK3 in scaffolds after implanting for one months in rats and corresponding fluorescence intensity statistics. (d) IF staining of KCNN3 and KCNH1 in scaffolds after implanting for one months in rats and corresponding fluorescence intensity statistics. n = 20 per group. Data are expressed as mean ± SD. ∗ for p < 0.05; ∗∗ for p < 0.01; ∗∗∗ for p < 0.001.
Anti Frem1, supplied by Proteintech, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti frem1/product/Proteintech
Average 91 stars, based on 1 article reviews
anti frem1 - by Bioz Stars, 2026-06
91/100 stars
  Buy from Supplier

91
R&D Systems recombinant frem1 protein
FIGURE 1 <t>Frem1</t> is expressed in the cNCC mesenchyme during midfacial morphogenesis. The bilaterally paired facial growth centers that form the midface are shown in an intact GD11 embryo (A), after microdissection (B), and after enzymatic digestion to separate the ectodermal epithelium and cNCC-derived mesenchyme (C–F). Gene expression in epithelial and mesenchymal compartments of GD11 MNP and MxP tissue was determined by qPCR (G,H). Individual values are plotted along with the mean ± SEM of four independently collected and pooled tissue samples. Whole-mount tissue (I) and sections through the facial growth centers (J–L) were stained by ISH to visualize expression of Frem1 (I–J), Frem2 (K), and Fras1 (L). At GD11, the facial growth centers fuse to form a lambdoidal junction as shown in schematic (M). MNP, medial nasal process; MxP, maxillary process; LNP, lateral nasal process; MdP, mandibular process. Scale bars: 0.25 mm
Recombinant Frem1 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant frem1 protein/product/R&D Systems
Average 91 stars, based on 1 article reviews
recombinant frem1 protein - by Bioz Stars, 2026-06
91/100 stars
  Buy from Supplier

Image Search Results


IHC and IF staining of functional proteins. (a) H&E and Masson's staining of defect area after implantation of CPH/rGO-3/0 and CPH/rGO-3/0.6 scaffolds for one month. (b) OCN IHC and IF staining of CPH/rGO-3/0 and CPH/rGO-3/0.6 after implantation for one month and the corresponding OD value and fluorescence intensity statistics. (c) IF staining of FREM1 and ANK3 in scaffolds after implanting for one months in rats and corresponding fluorescence intensity statistics. (d) IF staining of KCNN3 and KCNH1 in scaffolds after implanting for one months in rats and corresponding fluorescence intensity statistics. n = 20 per group. Data are expressed as mean ± SD. ∗ for p < 0.05; ∗∗ for p < 0.01; ∗∗∗ for p < 0.001.

Journal: Bioactive Materials

Article Title: A continuous adhesion-enhanced osteogenic pathway in artificial scaffold drives cellular infiltration and condensed mineralization for rapid bone regeneration

doi: 10.1016/j.bioactmat.2026.02.026

Figure Lengend Snippet: IHC and IF staining of functional proteins. (a) H&E and Masson's staining of defect area after implantation of CPH/rGO-3/0 and CPH/rGO-3/0.6 scaffolds for one month. (b) OCN IHC and IF staining of CPH/rGO-3/0 and CPH/rGO-3/0.6 after implantation for one month and the corresponding OD value and fluorescence intensity statistics. (c) IF staining of FREM1 and ANK3 in scaffolds after implanting for one months in rats and corresponding fluorescence intensity statistics. (d) IF staining of KCNN3 and KCNH1 in scaffolds after implanting for one months in rats and corresponding fluorescence intensity statistics. n = 20 per group. Data are expressed as mean ± SD. ∗ for p < 0.05; ∗∗ for p < 0.01; ∗∗∗ for p < 0.001.

Article Snippet: Hematoxylin-Eosin (Solarbio, Beijing, China) Stain Kit, Masson's Trichrome Stain Kit (Solarbio, Beijing, China), OCN monoclonal antibody (ThermoFisher Scientific, USA) FREM1 and KCNN3 antibody (Bioss Antibodies, Beijing, China), ANK3 antibody (Proteintech, Wuhan, China), KCNH1 (Servicecbio, Wuhan, China) were used to stain the slice of specimens.

Techniques: Staining, Functional Assay, Fluorescence

FIGURE 1 Frem1 is expressed in the cNCC mesenchyme during midfacial morphogenesis. The bilaterally paired facial growth centers that form the midface are shown in an intact GD11 embryo (A), after microdissection (B), and after enzymatic digestion to separate the ectodermal epithelium and cNCC-derived mesenchyme (C–F). Gene expression in epithelial and mesenchymal compartments of GD11 MNP and MxP tissue was determined by qPCR (G,H). Individual values are plotted along with the mean ± SEM of four independently collected and pooled tissue samples. Whole-mount tissue (I) and sections through the facial growth centers (J–L) were stained by ISH to visualize expression of Frem1 (I–J), Frem2 (K), and Fras1 (L). At GD11, the facial growth centers fuse to form a lambdoidal junction as shown in schematic (M). MNP, medial nasal process; MxP, maxillary process; LNP, lateral nasal process; MdP, mandibular process. Scale bars: 0.25 mm

Journal: Developmental dynamics : an official publication of the American Association of Anatomists

Article Title: Frem1 activity is regulated by Sonic hedgehog signaling in the cranial neural crest mesenchyme during midfacial morphogenesis.

doi: 10.1002/dvdy.555

Figure Lengend Snippet: FIGURE 1 Frem1 is expressed in the cNCC mesenchyme during midfacial morphogenesis. The bilaterally paired facial growth centers that form the midface are shown in an intact GD11 embryo (A), after microdissection (B), and after enzymatic digestion to separate the ectodermal epithelium and cNCC-derived mesenchyme (C–F). Gene expression in epithelial and mesenchymal compartments of GD11 MNP and MxP tissue was determined by qPCR (G,H). Individual values are plotted along with the mean ± SEM of four independently collected and pooled tissue samples. Whole-mount tissue (I) and sections through the facial growth centers (J–L) were stained by ISH to visualize expression of Frem1 (I–J), Frem2 (K), and Fras1 (L). At GD11, the facial growth centers fuse to form a lambdoidal junction as shown in schematic (M). MNP, medial nasal process; MxP, maxillary process; LNP, lateral nasal process; MdP, mandibular process. Scale bars: 0.25 mm

Article Snippet: O9-1 cells were plated at 5 104 cells/mL (0.4 mL per well in a 24-well plate) in Matrigel-coated wells and allowed to attach in complete O9-1 media for 16 h. Recombinant FREM1 protein (R&D Systems, Minneapolis, MN) dissolved in DPBS was diluted to final concentrations of 7.5, 2.5, and 0.83 μg/mL in DMEM containing 1% FBS, and 400 μL treatment or DPBS vehicle media were added to each well.

Techniques: Laser Capture Microdissection, Derivative Assay, Gene Expression, Staining, Expressing

FIGURE 2 Frem1 expression overlaps with Shh pathway target Gli1 during midfacial morphogenesis. The spatial expression of Frem1 and Gli1 was assessed by ISH at key stages of midfacial morphogenesis. Embryonic stages and planes of section are depicted by schematics in the left column. GD10.25 embryos were sectioned to visualize nascent MNP, LNP (A–C, plane of section 1), or MxP tissues (D–F, plane of section 2). GD11 embryos were sectioned to visualize MNP and LNP tissues along their proximal to distal axes (G–I, plane of section 3). GD13 embryos were sectioned to visualize the MxP-derived palatal shelves situated vertically along the sides of the tongue (J–L, plane of section 4). Staining is shown on adjacent sections for each stage/plane of section. Areas of apparent overlap in Gli1 and Frem1 expression are shown in schematics (C,F,I,L). MNP, medial nasal process; MxP, maxillary process; LNP, lateral nasal process; MdP, mandibular process; T, tongue; PS, palatal shelf. Scale bar: 0.25 mm

Journal: Developmental dynamics : an official publication of the American Association of Anatomists

Article Title: Frem1 activity is regulated by Sonic hedgehog signaling in the cranial neural crest mesenchyme during midfacial morphogenesis.

doi: 10.1002/dvdy.555

Figure Lengend Snippet: FIGURE 2 Frem1 expression overlaps with Shh pathway target Gli1 during midfacial morphogenesis. The spatial expression of Frem1 and Gli1 was assessed by ISH at key stages of midfacial morphogenesis. Embryonic stages and planes of section are depicted by schematics in the left column. GD10.25 embryos were sectioned to visualize nascent MNP, LNP (A–C, plane of section 1), or MxP tissues (D–F, plane of section 2). GD11 embryos were sectioned to visualize MNP and LNP tissues along their proximal to distal axes (G–I, plane of section 3). GD13 embryos were sectioned to visualize the MxP-derived palatal shelves situated vertically along the sides of the tongue (J–L, plane of section 4). Staining is shown on adjacent sections for each stage/plane of section. Areas of apparent overlap in Gli1 and Frem1 expression are shown in schematics (C,F,I,L). MNP, medial nasal process; MxP, maxillary process; LNP, lateral nasal process; MdP, mandibular process; T, tongue; PS, palatal shelf. Scale bar: 0.25 mm

Article Snippet: O9-1 cells were plated at 5 104 cells/mL (0.4 mL per well in a 24-well plate) in Matrigel-coated wells and allowed to attach in complete O9-1 media for 16 h. Recombinant FREM1 protein (R&D Systems, Minneapolis, MN) dissolved in DPBS was diluted to final concentrations of 7.5, 2.5, and 0.83 μg/mL in DMEM containing 1% FBS, and 400 μL treatment or DPBS vehicle media were added to each well.

Techniques: Expressing, Derivative Assay, Staining

FIGURE 3 Frem1 is regulated by the Shh pathway in cNCCs. O9-1 cNCCs were cultured with or without SHH ligand (0.4 μg/mL) and with or without the Smoothened antagonist vismodegib (Vismo, 100 nM) (A,B). SHH ligand caused an increase in Gli1 and Frem1 expression, which was blocked by the addition of vismodegib. Expression of Gli1 and Frem1 are increased in cNCCs expressing a constitutively active form of human Smoothened (SMOM2) relative to a GFP expressing line (C,D). cNCCs cultured with the Smoothened agonist SAG (50 nM) similarly demonstrated increased expression of Gli1 and Frem1 compared to vehicle alone (E–F). Values represent the mean ± SEM of N = 5 biological replicates for each condition. *P < 0.05, ** P < 0.01 (ANOVA with Tukey's post hoc test or two-tailed t-test)

Journal: Developmental dynamics : an official publication of the American Association of Anatomists

Article Title: Frem1 activity is regulated by Sonic hedgehog signaling in the cranial neural crest mesenchyme during midfacial morphogenesis.

doi: 10.1002/dvdy.555

Figure Lengend Snippet: FIGURE 3 Frem1 is regulated by the Shh pathway in cNCCs. O9-1 cNCCs were cultured with or without SHH ligand (0.4 μg/mL) and with or without the Smoothened antagonist vismodegib (Vismo, 100 nM) (A,B). SHH ligand caused an increase in Gli1 and Frem1 expression, which was blocked by the addition of vismodegib. Expression of Gli1 and Frem1 are increased in cNCCs expressing a constitutively active form of human Smoothened (SMOM2) relative to a GFP expressing line (C,D). cNCCs cultured with the Smoothened agonist SAG (50 nM) similarly demonstrated increased expression of Gli1 and Frem1 compared to vehicle alone (E–F). Values represent the mean ± SEM of N = 5 biological replicates for each condition. *P < 0.05, ** P < 0.01 (ANOVA with Tukey's post hoc test or two-tailed t-test)

Article Snippet: O9-1 cells were plated at 5 104 cells/mL (0.4 mL per well in a 24-well plate) in Matrigel-coated wells and allowed to attach in complete O9-1 media for 16 h. Recombinant FREM1 protein (R&D Systems, Minneapolis, MN) dissolved in DPBS was diluted to final concentrations of 7.5, 2.5, and 0.83 μg/mL in DMEM containing 1% FBS, and 400 μL treatment or DPBS vehicle media were added to each well.

Techniques: Cell Culture, Expressing, Two Tailed Test

FIGURE 5 FREM1 promotes concentration-dependent cNCC proliferation. Scratch assays were performed on O9-1 cNNCs ± recombinant FREM1, and migration rate was determined over the period of scratch closure for up to 8 h. FREM1 had no impact on the rate of O9-1 cNCC migration at any concentration tested (A). Representative images from vehicle- and 7.5 μg/mL FREM1-treated cells show scratch closure over time (B–G). EdU incorporation was used to assess cell proliferation in FREM1-treated O9-1 cNCCs. Addition of recombinant FREM1 protein to culture media increased proliferation in a concentration-dependent manner (H). Representative images of vehicle- and FREM1-treated O9-1 cNCCs stained with Hoechst (blue) and EdU (green) (I,J). Values represent the mean ± SEM of N = 3 biological replicates for each condition. *P < 0.05, **P < 0.01 (one-way ANOVA)

Journal: Developmental dynamics : an official publication of the American Association of Anatomists

Article Title: Frem1 activity is regulated by Sonic hedgehog signaling in the cranial neural crest mesenchyme during midfacial morphogenesis.

doi: 10.1002/dvdy.555

Figure Lengend Snippet: FIGURE 5 FREM1 promotes concentration-dependent cNCC proliferation. Scratch assays were performed on O9-1 cNNCs ± recombinant FREM1, and migration rate was determined over the period of scratch closure for up to 8 h. FREM1 had no impact on the rate of O9-1 cNCC migration at any concentration tested (A). Representative images from vehicle- and 7.5 μg/mL FREM1-treated cells show scratch closure over time (B–G). EdU incorporation was used to assess cell proliferation in FREM1-treated O9-1 cNCCs. Addition of recombinant FREM1 protein to culture media increased proliferation in a concentration-dependent manner (H). Representative images of vehicle- and FREM1-treated O9-1 cNCCs stained with Hoechst (blue) and EdU (green) (I,J). Values represent the mean ± SEM of N = 3 biological replicates for each condition. *P < 0.05, **P < 0.01 (one-way ANOVA)

Article Snippet: O9-1 cells were plated at 5 104 cells/mL (0.4 mL per well in a 24-well plate) in Matrigel-coated wells and allowed to attach in complete O9-1 media for 16 h. Recombinant FREM1 protein (R&D Systems, Minneapolis, MN) dissolved in DPBS was diluted to final concentrations of 7.5, 2.5, and 0.83 μg/mL in DMEM containing 1% FBS, and 400 μL treatment or DPBS vehicle media were added to each well.

Techniques: Concentration Assay, Recombinant, Migration, Staining

FIGURE 4 GLI binding to the Frem1 promoter during facial morphogenesis. GLI3 ChIP-seq data from GD11.5 whole face (MNP, MxP, LNP, MdP) were analyzed for GLI3 binding at Shh pathway target genes. GLI3 peaks (rectangles below ChIP-seq tracks) were present at both RefSeq56 annotated transcription start sites for Frem1 (A) but not Frem2 (B) or Frem3 (C). GLI3 ChIP-seq signal at the Frem1 promoters was comparable to GLI3 signal at the promoters of known Shh targets Gli1, Ccnd2, and Foxf2 (D–F).

Journal: Developmental dynamics : an official publication of the American Association of Anatomists

Article Title: Frem1 activity is regulated by Sonic hedgehog signaling in the cranial neural crest mesenchyme during midfacial morphogenesis.

doi: 10.1002/dvdy.555

Figure Lengend Snippet: FIGURE 4 GLI binding to the Frem1 promoter during facial morphogenesis. GLI3 ChIP-seq data from GD11.5 whole face (MNP, MxP, LNP, MdP) were analyzed for GLI3 binding at Shh pathway target genes. GLI3 peaks (rectangles below ChIP-seq tracks) were present at both RefSeq56 annotated transcription start sites for Frem1 (A) but not Frem2 (B) or Frem3 (C). GLI3 ChIP-seq signal at the Frem1 promoters was comparable to GLI3 signal at the promoters of known Shh targets Gli1, Ccnd2, and Foxf2 (D–F).

Article Snippet: O9-1 cells were plated at 5 104 cells/mL (0.4 mL per well in a 24-well plate) in Matrigel-coated wells and allowed to attach in complete O9-1 media for 16 h. Recombinant FREM1 protein (R&D Systems, Minneapolis, MN) dissolved in DPBS was diluted to final concentrations of 7.5, 2.5, and 0.83 μg/mL in DMEM containing 1% FBS, and 400 μL treatment or DPBS vehicle media were added to each well.

Techniques: Binding Assay, ChIP-sequencing

FIGURE 6 Frem1 expression is diminished by Shh pathway inhibition during pathogenesis of midfacial hypoplasia/cleft lip. In utero exposure to the Shh pathway antagonist cyclopamine from GD8.25 to 9.5 disrupts midfacial morphogenesis, resulting in either midfacial hypoplasia (B) or cleft lip (C) compared to control (A), as shown at GD17. Frontonasal prominence (FNP) tissue that gives rise to the MNPs and LNPs was microdissected from vehicle- and cyclopamine-exposed embryos at GD9.25, and gene expression was determined by qPCR (D). Expression data from pooled tissue of an entire litter are shown as individual points along with mean ± SEM. Expression of both Gli1 and Frem1 was significantly reduced in FNP tissue from embryos exposed to cyclopamine vs vehicle alone. * P < 0.05, ** P < 0.01 (two-tailed t-test). Sections through MNP and LNP tissue produced from GD10 vehicle- and cyclopamine-exposed embryos were stained by ISH to visualize expression of Gli1 (E,F) and Frem1 (G,H). Dashed outlines surround the mesenchyme of the MNP and LNP tissues. Cyclopamine exposure reduced expression of Gli1 and Frem1 in the MNP mesenchyme. MNP, medial nasal process; LNP, lateral nasal process; NE, neuroectoderm. Scale bar: 0.125 mm

Journal: Developmental dynamics : an official publication of the American Association of Anatomists

Article Title: Frem1 activity is regulated by Sonic hedgehog signaling in the cranial neural crest mesenchyme during midfacial morphogenesis.

doi: 10.1002/dvdy.555

Figure Lengend Snippet: FIGURE 6 Frem1 expression is diminished by Shh pathway inhibition during pathogenesis of midfacial hypoplasia/cleft lip. In utero exposure to the Shh pathway antagonist cyclopamine from GD8.25 to 9.5 disrupts midfacial morphogenesis, resulting in either midfacial hypoplasia (B) or cleft lip (C) compared to control (A), as shown at GD17. Frontonasal prominence (FNP) tissue that gives rise to the MNPs and LNPs was microdissected from vehicle- and cyclopamine-exposed embryos at GD9.25, and gene expression was determined by qPCR (D). Expression data from pooled tissue of an entire litter are shown as individual points along with mean ± SEM. Expression of both Gli1 and Frem1 was significantly reduced in FNP tissue from embryos exposed to cyclopamine vs vehicle alone. * P < 0.05, ** P < 0.01 (two-tailed t-test). Sections through MNP and LNP tissue produced from GD10 vehicle- and cyclopamine-exposed embryos were stained by ISH to visualize expression of Gli1 (E,F) and Frem1 (G,H). Dashed outlines surround the mesenchyme of the MNP and LNP tissues. Cyclopamine exposure reduced expression of Gli1 and Frem1 in the MNP mesenchyme. MNP, medial nasal process; LNP, lateral nasal process; NE, neuroectoderm. Scale bar: 0.125 mm

Article Snippet: O9-1 cells were plated at 5 104 cells/mL (0.4 mL per well in a 24-well plate) in Matrigel-coated wells and allowed to attach in complete O9-1 media for 16 h. Recombinant FREM1 protein (R&D Systems, Minneapolis, MN) dissolved in DPBS was diluted to final concentrations of 7.5, 2.5, and 0.83 μg/mL in DMEM containing 1% FBS, and 400 μL treatment or DPBS vehicle media were added to each well.

Techniques: Expressing, Inhibition, In Utero, Control, Gene Expression, Two Tailed Test, Produced, Staining